NCT06083909 is a clinical trial in Sarcopenic Obesity, sponsored by University of Central Florida.

Who is sponsoring NCT06083909?

NCT06083909 is sponsored by University of Central Florida.

What condition does NCT06083909 study?

NCT06083909 studies Sarcopenic Obesity, Diabetes.

Is NCT06083909 still recruiting?

NCT06083909 is currently completed. Last updated 19 October 2023.

Last reviewed 2023-10-19 · How we verify

NCT06083909

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sarcopenic Obesity in the Elderly

Completed Last updated 19 October 2023

What this trial tests

trial in Sarcopenic Obesity in 97 participants. Completed in 8 May 2023.

Timeline

6 April 2022

Primary endpoint
19 April 2023

8 May 2023

Quick facts

Lead sponsor	University of Central Florida
Status	Completed
Study type	OBSERVATIONAL
Enrollment	97
Start date	6 April 2022
Primary completion	19 April 2023
Estimated completion	8 May 2023
Sites	1 location across United States

Conditions studied

Sarcopenic Obesity — all drugs for Sarcopenic Obesity →
Diabetes — all drugs for Diabetes →

Sponsor

University of Central Florida

Who can join

Adults 65 to 85, any sex, with Sarcopenic Obesity or Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ageing is associated with progressive and generalized loss of muscle mass and muscle function, also known as Sarcopenia. Increasingly, obesity has become a compounding factor in ageing-related sarcopenia. The coexistence of obesity and sarcopenia is termed sarcopenic obesity (SO). Older adults with SO are at higher risks of developing diabetes, hypertension, stroke, cardiovascular diseases, and cognitive dysfunction than those older adults who suffer from sarcopenia alone or obesity alone. However, there is insufficient information with regard to the interplay between obesity and sarcopenia. The primary objective of this study is to investigate the impact of SO on insulin resistance in people aged 65-85. Our hypothesis is that SO positively influences insulin resistance in the elderly. We propose to investigate sarcopenia and obesity as risk factors for insulin resistance in the geriatric (65-85 years old) population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sarcopenic Obesity

Currently open trials in the same condition.

NCT07154719 — GLP-1R Actions on Muscle and the Skeleton · Phase 4 · recruiting
NCT07035483 — Changes in Fat and Muscle Tissue Function and Their Impact on Metabolic Health After Bariatric Surgery · active not recruiting
NCT06600581 — Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness · Phase 2 · active not recruiting
NCT06826963 — Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study · NA · recruiting
NCT06822504 — Prevalence of Sarcopenic Obesity in COPD · recruiting

Other University of Central Florida trials

Trials by the same sponsor.

NCT07203430 — Biopsychosocial Factors and Muscle Morphology After a Resistance Exercise · NA · completed
NCT07214883 — UCF MammoChat: Image Repository · recruiting
NCT06999057 — Quadriceps Motor Unit Adaptation to Simulated Knee Injury · NA · not yet recruiting
NCT06979713 — Yoga, Education, and Nidra (YEN) for Chronic Low Back Pain: A Pilot Study on Pain Modulation, Well-Being, and Sleep · NA · not yet recruiting
NCT06512168 — Measuring Aided Language Development · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06083909 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Central Florida
Last refreshed: 19 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06083909.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing